Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Auris Medical's Second Phase III Tinnitus Trial Disappoints

Executive Summary

Auris Medical Holding's investigational tinnitus product, Keyzilen, has failed to meet its primary efficacy endpoint in an interim analysis of a second Phase III trial, adding to a series of clinical disappointments over the past few years for the Swiss biotech.



Related Content

Auris Sees A Window To Treat Profound Hearing Loss Despite Phase III Failure
Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts